ClinicalTrials.gg
CompletedNCT03485365Updated Mar 22, 2024Results posted

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

A Phase 1 interventional study of GSK3858279 IV and GSK3858279 SC in Pain, Inflammatory, sponsored by GlaxoSmithKline. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Pain by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Pain · GlaxoSmithKline.

Enrollment
11th of 30
97 · median 35
Started
2018
with 1 other
Phase 1
16 of 30
none open now
Registered
24th of 30
by date

Among the 30 studies in Pain by GlaxoSmithKline, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 16 in phase 1, and was the 24th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 30 studies in Pain by GlaxoSmithKline is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Pain by GlaxoSmithKline as a file.
02

Study summary

This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of either a single intravenous (IV) or a single subcutaneous (SC) dose. Approximately 48 healthy participants will be enrolled in 6 cohorts and randomized to 3:1 ratio (GSK3858279 or placebo). Part B will evaluate safety, tolerability, efficacy (pain), PK, TE and immunogenicity after repeat SC dosing. Approximately 50 OA participants will be randomized in a parallel group design to receive either GSK3858279 or placebo in a 1:1 ratio.

03

Conditions studied

  • Pain, Inflammatory

Keywords

  • Pain
  • Osteoarthritis of the knee
  • Target engagement
  • GSK3858279
  • Pharmacokinetics
  • Sequential
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part A:

  • Participants between 18 and 65 years of age inclusive, at the time of signing the .
  • Volunteers who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Body weight within the range 50 to 100 kilogram (kg) and (BMI) within the range 18 to 32 kilogram per meter square (kg/m\^2) (inclusive).
  • Male participants are eligible to participate if they agree to the following for at least 28 weeks after the dose of study intervention: Refrain from donating sperm PLUS either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR must agree to use /barrier as detailed below: agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of who is not currently pregnant.
  • A female participant is eligible to participate if she is of non-.
  • Capable of giving signed informed consent.

For Part B:

  • Age between 40 and 75 years of age inclusive, at the time of signing the informed consent.
  • OA of the index knee as defined by symptomatic for >=6 months with a clinical diagnosis of OA as per American College of Rheumatology (ACR) clinical diagnosis criteria.
  • Average of daily pain score >=4 and \<=9 by 11 point NRS (0 to 10) in index knee over 7 days prior to dosing (Day-7 to Day-1). Data should be recorded on at least 5 of 7 occasions by the participant to obtain a valid Baseline value.
  • Kellgren and Lawrence (KL) score >=2 on X-ray obtained during screening. In addition, for participants with bilateral Knee OA, the index knee is determined at Baseline as the participant reported most painful knee over the 4 weeks prior to Baseline.
  • A history of insufficient pain relief from, or inability to tolerate, or to, oral Non-steroidal anti-inflammatory drugs (NSAIDs).
  • A participant must be willing and able to understand and participate in all scheduled evaluations and to complete all required tests and procedures including the use of patient diaries. This will be judged by the Investigator during the screening period.
  • BMI within the range 19-34.9 kg/m\^2 (inclusive)
  • Male participants are eligible to participate if they agree to the following for at least 28 weeks after the dose of study intervention: refrain from donating sperm PLUS either: Be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception/barrier as detailed: Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
  • A female participant is eligible to participate if she is of non-reproductive potential.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

For Part A:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Personal or family history of cardiomyopathy.
  • Abnormal blood pressure at screening as determined by the investigator.
  • History of symptomatic herpes zoster.
  • Evidence of active or latent tuberculosis (TB) as documented by medical history, examination, and TB testing with a positive (not indeterminate) QuantiFERON test.
  • Significant allergies to humanized monoclonal antibodies as per principal investigator's and GlaxoSmithKline (GSK) medical monitor's judgments.
  • History or evidence of multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Lymphoma, leukemia, or any except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • (ALT) >1.5 times (ULN).
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • (QTc) >450 milliseconds (msec).
  • History of Stevens Johnson Syndrome.
  • Known immunodeficiency.
  • Participants with a chronic infection (example given [e.g.], osteomyelitis), who have been receiving treatment within three months prior to dosing or individuals with an active infection.
  • Previous or current history of bleeding diathesis.
  • Previous history of hypertrophic or keloid scarring.
  • Intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing until final follow-up visit.
  • (s), or plans to receive such vaccines within 1 month of screening until final follow-up visit.
  • Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
  • Treatment with antiplatelet or anticoagulant agents within 7 days of dosing.
  • Major surgery (as per investigator's judgment) within 3 months prior to dosing.
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 3 months.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrolment or past participation in any other clinical study involving an study intervention or any other type of medical research within the last 30 days, 5 half-lives or twice the duration of the biological product before dosing day in the current study.
  • Presence of surface antigen (HBsAg) at screening.
  • Presence of the Hepatitis B core antibody (HBcAb) at screening.
  • Positive antibody test result at screening.
  • Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
  • Abnormal clinically significant echocardiogram at screening, as assessed by the investigator.
  • Cardiac troponin levels out of normal range at screening.
  • Positive pre-study drug/alcohol screen.
  • Positive (HIV) antibody test.
  • Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of >21 units for males and >14 units for females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Smokelyser levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Regular use of known drugs of abuse.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

For Part B:

  • Diagnosis of one or more of the following, as per medical records: Significant pain in any joint other than the index knee or any referred pain that would impact ability to assess pain in the index knee as per investigator's judgement (Pain in other locations should be less than pain in target knee).
  • Current inflammatory arthritis such as rheumatoid arthritis, disorder affecting joints, seronegative spondyloarthritis, gout or pseudogout in any joint (defined as acute episodic attacks of swollen, painful joint in a participant with X-Ray chondrocalcinosis or calcium pyrophosphate dehydrate [CPPD] crystals).
  • History of gout or pseudogout in any large joint.
  • History or evidence of infectious arthritis, Paget's disease, ochronosis, Wilson's disease, primary osteochondromatosis, osteonecrosis and other causes of significant joint disease osteoarthritis as determined by the investigator.
  • History of fibromyalgia.
  • Current immunodeficiency diseases.
  • Current osteoporosis with symptomatic vertebral or hip fractures.
  • Current regional pain syndromes caused by lumbar or cervical compressions with radiculopathy.
  • History of significant medical illness in the opinion of the investigator would interfere with the study procedures and / or assessments.
  • Symptomatic herpes zoster within 3 months prior to screening.
  • Evidence of active or latent TB as documented by medical history, examination and TB testing: either a positive tuberculin skin test (TST; defined as a skin induration >5 millimeter (mm) at 48 to 72 hours, regardless of Bacillus Calmette-Guerin (BCG) or other vaccination history) or a positive (not indeterminate) QuantiFERON test.
  • History of significant allergies to humanized monoclonal antibodies.
  • History or evidence of clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linearIgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis.
  • History of malignancy within the last 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
  • Breast cancer within the past 10 years.
  • ALT >1.5 times the ULN.
  • Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent)
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • QTc >450 msec or QTc >480 msec in participants with bundle branch block.
  • History of primary cardiomyopathy and any major cardiac or vascular event within the last 6 months, including and not limited to myocardial infarction, unstable angina, cerebrovascular event, peripheral arterial or venous thrombosis.
  • Current or history of renal disease, or estimated \<60 mL/minute/1.73/ m\^2 or serum creatinine >1.5 times the ULN or urine albumin:creatine ratio of >300mg/g at screening.
  • Planned surgical procedure over the duration of the study.
  • Previous or current history of bleeding diathesis, excessive bleeding or coagulation disorders.
  • History of Stevens Johnson Syndrome.
  • Participants with active, recurrent or chronic infection (e.g., osteomyelitis), who have been receiving treatment within three months prior to dosing or individuals with an active infection.
  • History of significant trauma or surgery to a knee, hip or shoulder within the last 6 months.
  • Radiographic evidence of sub-chondral fractures or radiographic abnormalities not consistent with osteoarthritis of the index knee at screening.
  • Live vaccine(s) within 1 month prior to screening, or plans to receive such vaccines during the study.
  • Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
  • Intra-articular therapy within 3 months prior to signing the .
  • 's, including corticosteroids (parenteral within 3 months of screening; oral within 1 month of screening).
  • Unable or unwilling to discontinue all pain medication including topical analgesic or adjunctive treatment.
  • Major surgery (as per investigator's judgement) within 3 months prior to dosing.
  • Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the dosing day.
  • Current enrolment or past participation in a clinical study of an investigational drug intervention within the last 3 months or 5 half-lives (whichever is longer) of signing consent.
  • Positive HIV antibody test.
  • Presence of HBsAg at screening.
  • Positive Hepatitis C antibody test result.
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Positive coronavirus (Coronavirus Disease strain 19 [COVID-19]: Severe acute respiratory syndrome- Coronavirus-strain 2 [SARS-CoV-2] polymerase chain reaction [PCR] test of a combined throat and nasopharyngeal swab).
  • Clinically significant abnormal at screening, as assessed by the investigator.
  • Cardiac troponin or N-terminal pro B-type natriuretic peptide (NT-proBNP) levels out of normal range at screening.
  • A positive pre-study drug/alcohol screen at screening.
  • Regular alcohol consumption within 6 months prior to signing the informed consent defined as: an average weekly intake of >14 units for males and >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Regular use of known drugs of abuse
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1: GSK3858279

    Eligible participants will receive GSK3858279 via IV route.

    Drug: GSK3858279 IV

  • Experimental
    Part A: Cohort 2: GSK3858279

    Eligible participants will receive GSK3858279 via IV route.

    Drug: GSK3858279 IV

  • Experimental
    Part A: Cohort 3: GSK3858279

    Eligible participants will receive GSK3858279 via IV route.

    Drug: GSK3858279 IV

  • Experimental
    Part A: Cohort 4: GSK3858279

    Eligible participants will receive GSK3858279 via IV route.

    Drug: GSK3858279 IV

  • Experimental
    Part A: Cohort 5: GSK3858279

    Eligible participants will receive GSK3858279 via IV route.

    Drug: GSK3858279 IV

  • Experimental
    Part A: Cohort 6: GSK3858279

    Eligible participants will receive GSK3858279 via SC route.

    Drug: GSK3858279 SC

  • Placebo comparator
    Part A: Placebo

    Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.

    Drug: Placebo matching to GSK3858279 (SC or IV)

  • Experimental
    Part B: GSK3858279

    Eligible participants will receive GSK3858279 via SC route.

    Drug: GSK3858279 SC

  • Placebo comparator
    Part B: Placebo

    Eligible participants will receive placebo matching to GSK3858279 via SC route.

    Drug: Placebo matching to GSK3858279 (SC)

Interventions

  • GSK3858279 will be available as solution for injection to be administered via IV route.

  • GSK3858279 will be available as solution for injection to be administered via SC route.

  • DrugPlacebo matching to GSK3858279 (SC or IV)

    Placebo will be available as sodium chloride solution to be administered via SC or IV route.

  • DrugPlacebo matching to GSK3858279 (SC)

    Placebo will be available as sodium chloride solution to be administered via SC route.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

    Time frame: Up to 141 days

  2. Part B: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

    Time frame: Up to 141 days

  3. Part A: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis

    The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  4. Part B: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis

    The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  5. Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings

    Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  6. Part B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings

    Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  7. Part A: Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  8. Part B: Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

    Time frame: Up to 141 days

  9. Part B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8

    Change from Baseline in knee pain due to Osteoarthritis were reported by average of daily pain numeric rating scale (NRS) at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicates no pain, and 10 indicates the worst possible pain. For each participant, the mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.

    Time frame: Baseline (Day 1) and Week 8

  10. Part B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8

    Change from Baseline in worst knee pain intensity were assessed using NRS at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicated no pain, and 10 indicated worst possible pain. The mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.

    Time frame: Baseline (Day 1) and Week 8

Secondary outcomes

  1. Part A: Serum Concentrations of GSK3858279 Following a Single IV Dose

    Time frame: Up to 141 days

  2. Part A: Serum Concentrations of GSK3858279 Following a Single SC Dose

    Time frame: Up to 141 days

  3. Part B: Serum Concentration of GSK3858279 Following Repeat SC Dose

    Time frame: Up to 141 days

  4. Part A: Area Under the Time-Concentration Curve (AUC) Over the Dosing Interval (0-tau) (AUC[0-tau]) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  5. Part A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  6. Part A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  7. Part A: AUC(0-tau) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  8. Part A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  9. Part A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  10. Part B: AUC(0-tau) Following a Repeat SC Dose of GSK3858279

    Time frame: Baseline and Week 8

  11. Part B: AUC(0-t) Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  12. Part B: AUC(0-infinity) Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  13. Part A: Maximum Concentration (Cmax) After a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  14. Part A: Maximum Concentration (Cmax) After a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  15. Part B: Cmax After Repeat SC Dose of GSK3858279

    Time frame: Baseline and Week 8

  16. Part A: Half-life (t1/2) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  17. Part A: Half-life (t1/2) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  18. Part B: t1/2 Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  19. Part A: Clearance (CL) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  20. Part A: Clearance (CL) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  21. Part B: CL Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  22. Part A: Volume of Distribution at Steady State (Vss) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  23. Part A: Volume of Distribution at Steady State (Vss) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  24. Part B: Vss Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  25. Part A: Volume of Distribution (V) Following a Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  26. Part A: Volume of Distribution (V) Following a Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  27. Part B: Volume of Distribution (V) Following a Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  28. Part A: Free Chemokine Ligand 17 (CCL17) Levels in Serum Following Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  29. Part A: CCL17 Levels in Serum Following Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  30. Part B: Free CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

  31. Part A: Total CCL17 Levels in Serum Following Single IV Dose of GSK3858279

    Time frame: Up to 141 days

  32. Part A: Total CCL17 Levels in Serum Following Single SC Dose of GSK3858279

    Time frame: Up to 141 days

  33. Part B: Total CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279

    Time frame: Up to 141 days

07

Results

Posted Mar 22, 2024
Limitations and caveats
Data has not been disclosed for pharmacokinetic parameters for this study as the development of the compound (GSK3858279) is still ongoing in another phase II study (NCT05838742) to fully understand the PK trends/parameters. We will disclose data for all pre-specified secondary PK parameters by 15-DEC-2027.

Participant flow

This was a 2-part study. Part A was a sequential group with a single ascending dose escalation in healthy participants. Single intravenous (IV) doses and a single subcutaneous (SC) dose were investigated in separate cohorts of participants. Part B was parallel group with repeat SC dosing of GSK3858279 or matching placebo in participants with Knee Osteoarthritis.

Participant flow — Overall Study
MilestonePart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled PlaceboPart B: Cohort 7: GSK3858279Part B: Placebo
Started666666132424
Completed666566122424
Not completed000100100
Withdrew: Protocol violation000100100

Outcome measures

PrimaryPart A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled Placebo
Participants with TEAEs22466612
Participants with SAEs0000000
PrimaryPart B: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is defined as an AE that occurred on or after the first dose date of study intervention. SAEs is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part B: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
ParticipantsPart B: Cohort 7: GSK3858279Part B: Placebo
Participants with TEAEs2115
Participants with SAEs00
PrimaryPart A: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis

The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis
ParticipantsPart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled Placebo
Hematology0000000
Clinical Chemistry0000000
Urinalysis0000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis

The parameters evaluated for Hematology were Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, mean corpuscular Hg, mean corpuscular volume, Monocytes, Platelet count, Red blood cells, Reticulocytes, Total Neutrophils, White blood cells count (WBC). For Clinical Chemistry- Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct bilirubin, Glucose, Potassium, Sodium, Total bilirubin, Total protein, TroponinT, N-terminal pro B-type natriuretic peptide (NT-ProBNP) and Urea. For Urinalysis-Urine bilirubin, Occult blood, Glucose, Ketones, Nitrates, pH, Protein, Specific gravity, Urobilinogen and Leukocyte Esterase for detecting WBC. Changes from baseline in hematology, clinical chemistry and urinalysis were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry Laboratory Parameters and Urinalysis
ParticipantsPart B: Cohort 7: GSK3858279Part B: Placebo
Hematology00
Clinical Chemistry00
Urinalysis00
PrimaryPart A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings

Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings
ParticipantsPart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled Placebo
Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings0000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings

Twelve-lead Electrocardiogram (ECG) were performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, Uncorrected QT and corrected QT intervals (QTc) intervals. Changes from baseline in ECG findings were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings
ParticipantsPart B: Cohort 7: GSK3858279Part B: Placebo
Part B: Number of Participants With Clinically Significant Changes in Electrocardiogram Findings00
PrimaryPart A: Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part A: Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsPart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled Placebo
Part A: Number of Participants With Clinically Significant Changes in Vital Signs0000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Vital Signs

Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Changes from baseline in vital signs were reviewed by the investigator, medical monitor and safety physician to determine clinical significance; the number of participants with clinically significant changes is reported.

Time frame:
Up to 141 days
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsPart B: Cohort 7: GSK3858279Part B: Placebo
Part B: Number of Participants With Clinically Significant Changes in Vital Signs00
PrimaryPart B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8

Change from Baseline in knee pain due to Osteoarthritis were reported by average of daily pain numeric rating scale (NRS) at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicates no pain, and 10 indicates the worst possible pain. For each participant, the mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Mean · Scores on a scale
Part B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8
Scores on a scalePart B: Cohort 7: GSK3858279Part B: Placebo
Part B: Change From Baseline in Knee Pain as Assessed by Average of Daily Pain Numeric Rating Scale at Week 8-2.82 ± 1.752-1.62 ± 1.709
Statistical analysis
  • Part B: Cohort 7: GSK3858279 vs Part B: Placebo · Median difference (net): -1.18 · 95% CI -2.15 to -0.20Posterior median difference (GSK3858279 - Placebo) and 95% credible interval is presented.
PrimaryPart B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8

Change from Baseline in worst knee pain intensity were assessed using NRS at Week 8. The pain NRS is an 11-point scale (ranging from 0-10) for self-reporting of average knee pain where 0 indicated no pain, and 10 indicated worst possible pain. The mean pain score prior to each visit was calculated as the average pain intensity in the 7 days prior to assessment visit. Participants were instructed to complete the pain NRS questionnaire at approximately the same time each day. A negative value change from baseline indicates an improvement. Baseline scores for each participant were assigned based on the first dosing visit.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Mean · Scores on a scale
Part B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8
Scores on a scalePart B: Cohort 7: GSK3858279Part B: Placebo
Part B: Change From Baseline in Worst Knee Pain Intensity as Assessed by Numeric Rating Scale at Week 8-2.89 ± 2.185-1.58 ± 2.057
Statistical analysis
  • Part B: Cohort 7: GSK3858279 vs Part B: Placebo · Median difference (net): -1.09 · 95% CI -2.29 to 0.12Posterior median difference (GSK3858279 - Placebo) and 95% credible interval is presented.
SecondaryPart A: Serum Concentrations of GSK3858279 Following a Single IV Dose
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Serum Concentrations of GSK3858279 Following a Single SC Dose
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Serum Concentration of GSK3858279 Following Repeat SC Dose
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Area Under the Time-Concentration Curve (AUC) Over the Dosing Interval (0-tau) (AUC[0-tau]) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: AUC(0-tau) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: AUC From Zero to Time t (0-t) (AUC[0-t]) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: AUC From Zero to Infinity (0-infinity) (AUC[0-infinity]) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: AUC(0-tau) Following a Repeat SC Dose of GSK3858279
Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryPart B: AUC(0-t) Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: AUC(0-infinity) Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Maximum Concentration (Cmax) After a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Maximum Concentration (Cmax) After a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Cmax After Repeat SC Dose of GSK3858279
Time frame:
Baseline and Week 8

Results for this outcome have not been posted.

SecondaryPart A: Half-life (t1/2) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Half-life (t1/2) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: t1/2 Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Clearance (CL) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Clearance (CL) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: CL Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Volume of Distribution at Steady State (Vss) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Volume of Distribution at Steady State (Vss) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Vss Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Volume of Distribution (V) Following a Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Volume of Distribution (V) Following a Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Volume of Distribution (V) Following a Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Free Chemokine Ligand 17 (CCL17) Levels in Serum Following Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: CCL17 Levels in Serum Following Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Free CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Total CCL17 Levels in Serum Following Single IV Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart A: Total CCL17 Levels in Serum Following Single SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

SecondaryPart B: Total CCL17 Levels in Serum Following Repeat SC Dose of GSK3858279
Time frame:
Up to 141 days

Results for this outcome have not been posted.

Adverse events

Collected over Part A and Part B: Up to 141 Days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1: GSK38582790/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 2: GSK38582790/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 3: GSK38582790/6 (0%)0/6 (0%)4/6 (66.7%)
Part A: Cohort 4: GSK38582790/6 (0%)0/6 (0%)6/6 (100%)
Part A: Cohort 5: GSK38582790/6 (0%)0/6 (0%)6/6 (100%)
Part A: Cohort 6: GSK38582790/6 (0%)0/6 (0%)6/6 (100%)
Part A: Pooled Placebo0/13 (0%)0/13 (0%)12/13 (92.3%)
Part B: Cohort 7: GSK38582790/24 (0%)0/24 (0%)21/24 (87.5%)
Part B: Placebo0/24 (0%)0/24 (0%)15/24 (62.5%)
Most frequent other events
Showing 10 of 100
Most frequent other events
EventPart A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled PlaceboPart B: Cohort 7: GSK3858279Part B: Placebo
NasopharyngitisInfections and infestations0/60/60/63/61/63/63/133/242/24
Dermatitis contactSkin and subcutaneous tissue disorders0/60/61/63/61/61/62/132/240/24
DiarrhoeaGastrointestinal disorders1/60/60/62/60/60/61/132/240/24
Catheter site bruiseGeneral disorders0/60/60/60/62/60/61/130/240/24
Skin lacerationInjury, poisoning and procedural complications0/60/60/60/62/60/60/130/240/24
HeadacheNervous system disorders0/60/60/62/61/61/63/132/245/24
CoughRespiratory, thoracic and mediastinal disorders0/60/60/60/61/62/61/130/240/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/60/60/60/61/62/62/130/240/24
Eye irritationEye disorders1/60/60/60/60/60/60/130/240/24
Abdominal pain upperGastrointestinal disorders0/60/60/61/60/60/60/131/241/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled PlaceboPart B: Cohort 7: GSK3858279Part B: PlaceboTotal
<=18 years0000000000
Between 18 and 65 years66566613171883
>=65 years00100007614
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled PlaceboPart B: Cohort 7: GSK3858279Part B: PlaceboTotal
Female102012081327
Male56465413161170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Cohort 1: GSK3858279Part A: Cohort 2: GSK3858279Part A: Cohort 3: GSK3858279Part A: Cohort 4: GSK3858279Part A: Cohort 5: GSK3858279Part A: Cohort 6: GSK3858279Part A: Pooled PlaceboPart B: Cohort 7: GSK3858279Part B: PlaceboTotal
ASIAN0101100104
BLACK OR AFRICAN AMERICAN0001000001
WHITE65645613232492
08

Study locations

5 sites
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Warsaw, 02-106, Poland
  • GSK Investigational Site
    Cambridge, CB2 2GG, United Kingdom
  • GSK Investigational Site
    London, NW10 7EW, United Kingdom
  • GSK Investigational Site
    Manchester, M13 9NQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Sep 2022, 51 months.

Results were first posted in Mar 2024, 1 year 6 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 51 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 2, 2018
StartActual
May 17, 2018
Primary completionActual
Sep 12, 2022
CompletionActual
Sep 12, 2022
Results first posted
Mar 22, 2024
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03485365
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 2, 2018
Start date
May 17, 2018
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022
Results posted
Mar 22, 2024
Last update
Mar 22, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denrakibart

Start the discussion